RU2002126615A - Рецептуры ранолазина пролонгированного действия - Google Patents
Рецептуры ранолазина пролонгированного действияInfo
- Publication number
- RU2002126615A RU2002126615A RU2002126615/14A RU2002126615A RU2002126615A RU 2002126615 A RU2002126615 A RU 2002126615A RU 2002126615/14 A RU2002126615/14 A RU 2002126615/14A RU 2002126615 A RU2002126615 A RU 2002126615A RU 2002126615 A RU2002126615 A RU 2002126615A
- Authority
- RU
- Russia
- Prior art keywords
- ranolazine
- patient
- hours
- dosage form
- plasma
- Prior art date
Links
- 230000002035 prolonged effect Effects 0.000 title claims 2
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 claims 9
- 229960000213 ranolazine Drugs 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 5
- 201000001068 Prinzmetal angina Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Способ лечения больного, страдающего сердечнососудистым заболеванием, выбранным из аритмии, вариантной стенокардии, стенокардии напряжения и инфаркта миокарда, введением фармацевтической лекарственной формы пролонгированного действия, включающей, по меньшей мере, 50% массовых ранолазина, в форме не более двух таблеток на дозу больному для поддержания уровней ранолазина в плазме больного при минимуме 850 нг основания/мл в течение, по меньшей мере, 24 ч, где дозу вводят с частотой, выбранной из одного раза, двух и трех раз в течение 24 ч.
2. Способ по п.1, где максимальный уровень ранолазина в плазме равен примерно 4000 нг основания/мл.
3. Способ по п.1, где фармацевтическую лекарственную форму вводят больному с частотой, выбранной из одного раза и двух раз в течение 24 ч.
4. Способ по п.1, где фармацевтическую лекарственную форму вводят больному двумя дозами в течение 24 ч, где каждая доза состоит из двух таблеток.
5. Способ по п.1, где фармацевтическая лекарственная форма включает примерно между 50 и 95% массовыми ранолазина.
6. Способ по п.1, где фармацевтическая лекарственная форма включает примерно от 70 до 80% массовых ранолазина.
7. Способ по п.1, где отношение пикового уровня к минимальному уровню ранолазина в плазме больного равно менее 4:1 в течение периода 24 ч.
8. Способ по п.1, где отношение пикового уровня к минимальному уровню ранолазина в плазме больного равно менее 3:1 в течение периода 24 ч.
9. Способ по п.1, где отношение пикового уровня к минимальному уровню ранолазина в плазме больного равно менее 2:1 в течение периода 24 ч.
10. Способ по п.1, где доза включает примерно от 500 до 1500 мг ранолазина.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/520,932 | 2000-03-08 | ||
| US09/520,932 US6479496B1 (en) | 1998-09-10 | 2000-03-08 | Methods for treating angina with ranolazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002126615A true RU2002126615A (ru) | 2004-03-20 |
Family
ID=24074628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002126615/14A RU2002126615A (ru) | 2000-03-08 | 2001-03-07 | Рецептуры ранолазина пролонгированного действия |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6479496B1 (ru) |
| EP (1) | EP1263439A2 (ru) |
| JP (2) | JP4108980B2 (ru) |
| CN (1) | CN1323664C (ru) |
| AU (3) | AU4009201A (ru) |
| BR (1) | BR0109091A (ru) |
| CA (1) | CA2402222C (ru) |
| CZ (1) | CZ20022996A3 (ru) |
| HU (1) | HUP0204409A3 (ru) |
| IL (1) | IL151575A0 (ru) |
| MX (1) | MXPA02008654A (ru) |
| NO (1) | NO20024270L (ru) |
| NZ (1) | NZ521292A (ru) |
| PL (1) | PL357273A1 (ru) |
| RU (1) | RU2002126615A (ru) |
| WO (1) | WO2001066093A2 (ru) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
| US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
| US6541014B2 (en) | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
| EP2332540A1 (en) | 2002-05-21 | 2011-06-15 | Cv Therapeutics, Inc. | Administration of ranolazine for the treatment of diabetes |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| AU2004258944B2 (en) | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| CA2533178C (en) | 2003-07-21 | 2014-03-11 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| WO2005009368A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
| AU2004264939A1 (en) | 2003-08-11 | 2005-02-24 | Middlebrook Pharmaceuticals, Inc. | Robust pellet |
| WO2005016278A2 (en) | 2003-08-12 | 2005-02-24 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| WO2005023184A2 (en) | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
| EP1663169A4 (en) | 2003-09-15 | 2010-11-24 | Middlebrook Pharmaceuticals In | ANTIBIOTICS, ITS USE AND FORMULATION |
| US8715727B2 (en) | 2004-07-02 | 2014-05-06 | Shionogi Inc. | Tablet for pulsed delivery |
| CA2593593A1 (en) * | 2005-01-06 | 2006-07-13 | Cv Therapeutics, Inc. | Sustained release pharmaceutical formulations comprising ranolazine |
| US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
| US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| CN100455288C (zh) * | 2006-06-26 | 2009-01-28 | 哈药集团制药总厂 | 一种盐酸雷诺嗪制剂配方 |
| US20080031947A1 (en) * | 2006-07-24 | 2008-02-07 | Cima Labs Inc. | Orally dissolvable/disintegrable lyophilized dosage forms containing protected |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| EP2117549A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| JP2010518181A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 心血管疾患の処置のためのラノラジンの使用 |
| JP2010518171A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 非冠微小血管疾患の処置のためのラノラジンの使用 |
| ATE509015T1 (de) * | 2007-03-07 | 2011-05-15 | Concert Pharmaceuticals Inc | Deuterierte piperazinderivate als verbindungen gegen angina |
| WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| RU2442585C2 (ru) * | 2007-05-31 | 2012-02-20 | Си Ви Терапьютикс, Инк. | Способ лечения диабета |
| JP2010528112A (ja) * | 2007-05-31 | 2010-08-19 | ギリアード・パロ・アルト・インコーポレイテッド | 糖尿病を治療する方法 |
| WO2008150565A2 (en) * | 2007-05-31 | 2008-12-11 | Cv Therapeutics, Inc. | Ranolazine for elevated brain-type natriuretic peptide |
| CN101835761A (zh) * | 2007-06-13 | 2010-09-15 | 奥斯拜客斯制药有限公司 | 取代的哌嗪 |
| US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
| BRPI0908428A2 (pt) * | 2008-02-06 | 2015-12-08 | Gilead Sciences Inc | uso de ranozalina para tratar a dor. |
| JP2012526848A (ja) * | 2009-05-14 | 2012-11-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｎｓ障害の治療のためのラノラジン |
| NO3175985T3 (ru) | 2011-07-01 | 2018-04-28 | ||
| EP2758053A1 (en) | 2011-09-21 | 2014-07-30 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| TW201717919A (zh) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
| WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
| JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス，インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン |
| US20250064799A1 (en) | 2021-12-31 | 2025-02-27 | Tenax Therapeutics, Inc. | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| IL81419A0 (en) * | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
| ES2177601T3 (es) * | 1989-06-23 | 2002-12-16 | Syntex Llc | Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. . |
| US5209933A (en) | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| JPH09188617A (ja) * | 1996-01-08 | 1997-07-22 | Pola Chem Ind Inc | 徐放性医薬組成物 |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| JP2000336032A (ja) * | 1999-05-26 | 2000-12-05 | Kissei Pharmaceut Co Ltd | ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物 |
-
2000
- 2000-03-08 US US09/520,932 patent/US6479496B1/en not_active Expired - Lifetime
-
2001
- 2001-03-07 AU AU4009201A patent/AU4009201A/xx active Pending
- 2001-03-07 HU HU0204409A patent/HUP0204409A3/hu unknown
- 2001-03-07 AU AU2001240092A patent/AU2001240092B8/en not_active Revoked
- 2001-03-07 CN CNB018061850A patent/CN1323664C/zh not_active Expired - Lifetime
- 2001-03-07 JP JP2001564746A patent/JP4108980B2/ja not_active Expired - Lifetime
- 2001-03-07 IL IL15157501A patent/IL151575A0/xx unknown
- 2001-03-07 NZ NZ521292A patent/NZ521292A/en not_active IP Right Cessation
- 2001-03-07 CA CA002402222A patent/CA2402222C/en not_active Expired - Lifetime
- 2001-03-07 MX MXPA02008654A patent/MXPA02008654A/es active IP Right Grant
- 2001-03-07 BR BR0109091-7A patent/BR0109091A/pt not_active Application Discontinuation
- 2001-03-07 RU RU2002126615/14A patent/RU2002126615A/ru unknown
- 2001-03-07 CZ CZ20022996A patent/CZ20022996A3/cs unknown
- 2001-03-07 WO PCT/US2001/007287 patent/WO2001066093A2/en active IP Right Grant
- 2001-03-07 PL PL01357273A patent/PL357273A1/xx not_active Application Discontinuation
- 2001-03-07 EP EP01914738A patent/EP1263439A2/en not_active Withdrawn
-
2002
- 2002-09-06 NO NO20024270A patent/NO20024270L/no not_active Application Discontinuation
-
2007
- 2007-09-20 JP JP2007243731A patent/JP2008069159A/ja active Pending
-
2008
- 2008-09-03 AU AU2008212005A patent/AU2008212005A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2402222C (en) | 2009-11-03 |
| NZ521292A (en) | 2008-07-31 |
| AU2001240092B8 (en) | 2004-12-02 |
| WO2001066093A2 (en) | 2001-09-13 |
| CZ20022996A3 (cs) | 2003-09-17 |
| US6479496B1 (en) | 2002-11-12 |
| HUP0204409A3 (en) | 2005-04-28 |
| CN1323664C (zh) | 2007-07-04 |
| AU2008212005A1 (en) | 2008-09-25 |
| CN1443069A (zh) | 2003-09-17 |
| JP2008069159A (ja) | 2008-03-27 |
| BR0109091A (pt) | 2005-02-15 |
| HUP0204409A2 (en) | 2003-05-28 |
| WO2001066093A3 (en) | 2002-03-14 |
| AU4009201A (en) | 2001-09-17 |
| IL151575A0 (en) | 2003-04-10 |
| EP1263439A2 (en) | 2002-12-11 |
| PL357273A1 (en) | 2004-07-26 |
| NO20024270L (no) | 2002-11-06 |
| CA2402222A1 (en) | 2001-09-13 |
| HK1058003A1 (en) | 2004-04-30 |
| MXPA02008654A (es) | 2004-09-06 |
| JP4108980B2 (ja) | 2008-06-25 |
| NO20024270D0 (no) | 2002-09-06 |
| JP2003525896A (ja) | 2003-09-02 |
| AU2001240092B2 (en) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002126615A (ru) | Рецептуры ранолазина пролонгированного действия | |
| EP1087775B1 (en) | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination | |
| CA2433035C (en) | Pharmaceutical compositions comprising amlodipine maleate | |
| AR022085A1 (es) | Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| RU2005124363A (ru) | Твердые пероральные дозируемые формы валсартана | |
| JP2002523370A5 (ru) | ||
| CA2456732A1 (en) | Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor | |
| Midtbø et al. | Verapamil compared with nifedipine in the treatment of essential hypertension | |
| RU2003100507A (ru) | Фармацевтические композиции | |
| CA2503719A1 (en) | Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases | |
| Brodsky et al. | Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study. | |
| Lindenberg et al. | Efficacy and safety of incremental doses of diltiazem for the treatment of stable angina pectoris | |
| CA2411882A1 (en) | Solid valsartan pharmaceutical compositions | |
| JP2006515299A5 (ru) | ||
| Weiner et al. | Efficacy and safety of sustained-release diltiazem in stable angina pectoris | |
| CA2508611A1 (en) | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines | |
| GR1004193B (el) | Φαρμακευτικη συνθεση περιεχουσα σιταλοπραμη | |
| RU2011131532A (ru) | Способ лечения бессонницы | |
| IL148777A (en) | Mirtazepine oral oral administration unit | |
| Tardif | Clinical efficacy of ivabradine | |
| JP2005525391A5 (ru) | ||
| Lee et al. | Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulations of motoprolol in healthy chinese subjects | |
| JP2003523385A5 (ru) | ||
| Nordlander et al. | Once-versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris: A randomized, double-blind, cross-over study |